Otsuka Holdings Co., Ltd.

OTCPK:OTSK.F Stock Report

Market Cap: US$39.9b

Otsuka Holdings Valuation

Is OTSK.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OTSK.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: OTSK.F ($76.1) is trading below our estimate of future cash flow value ($111.41)

Significantly Below Future Cash Flow Value: OTSK.F is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OTSK.F?

Key metric: As OTSK.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for OTSK.F. This is calculated by dividing OTSK.F's market cap by their current earnings.
What is OTSK.F's PE Ratio?
PE Ratio15.1x
EarningsJP¥405.23b
Market CapJP¥6.13t

Price to Earnings Ratio vs Peers

How does OTSK.F's PE Ratio compare to its peers?

The above table shows the PE ratio for OTSK.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average30.5x
TEVA Teva Pharmaceutical Industries
60.8x26.76%US$42.8b
RPRX Royalty Pharma
33.2x15.92%US$34.8b
ZTS Zoetis
11.5x3.50%US$30.4b
JAZZ Jazz Pharmaceuticals
16.7x17.70%US$15.6b
OTSK.F Otsuka Holdings
15.1x6.14%US$6.1t

Price-To-Earnings vs Peers: OTSK.F is good value based on its Price-To-Earnings Ratio (15.1x) compared to the peer average (30.5x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does OTSK.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

8 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NDOI Endo
0.3xn/aUS$1.76b
CRMD CorMedix
3.4x-3.24%US$637.58m
ORMP Oramed Pharmaceuticals
1.1xn/aUS$207.15m
SDEV Stablecoin Development
0.09xn/aUS$44.04m
OTSK.F 15.1xIndustry Avg. 16.2xNo. of Companies9PE01632486480+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: OTSK.F is good value based on its Price-To-Earnings Ratio (15.1x) compared to the US Pharmaceuticals industry average (16.2x).

Price to Earnings Ratio vs Fair Ratio

What is OTSK.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OTSK.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15.1x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate OTSK.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OTSK.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$93.67
0%
14.81%US$121.06US$71.60n/a12
Sep ’27US$76.10
US$89.23
+17.25%
15.27%US$116.19US$68.71n/a12
Aug ’27n/a
US$83.09
0%
11.05%US$98.63US$69.11n/a12
Jul ’27US$66.00
US$79.73
+20.81%
10.21%US$97.04US$67.99n/a12
Jun ’27n/a
US$78.81
0%
12.80%US$98.79US$62.92n/a12
May ’27US$64.57
US$77.09
+19.39%
11.71%US$94.58US$62.63n/a12
Apr ’27US$70.34
US$73.40
+4.35%
11.70%US$95.14US$63.01n/a12
Mar ’27US$67.11
US$69.48
+3.54%
10.60%US$84.53US$57.63n/a12
Feb ’27n/a
US$66.28
0%
12.75%US$81.77US$51.92n/a12
Jan ’27US$54.26
US$62.55
+15.27%
12.23%US$72.30US$51.42n/a11
Dec ’26US$58.42
US$61.62
+5.49%
11.77%US$70.77US$51.47n/a12
Nov ’26n/a
US$60.86
0%
12.86%US$71.38US$46.72n/a12
Oct ’26US$57.36
US$63.73
+11.11%
12.85%US$74.78US$48.95n/a12
Sep ’26n/a
US$62.95
0%
12.75%US$74.61US$48.83US$76.1011
Aug ’26n/a
US$60.71
0%
14.14%US$72.95US$47.75n/a11
Jul ’26n/a
US$62.28
0%
13.71%US$73.84US$49.69US$66.0012
Jun ’26n/a
US$62.50
0%
13.64%US$74.24US$49.96n/a12
May ’26n/a
US$63.32
0%
12.98%US$74.87US$52.48US$64.5712
Apr ’26n/a
US$61.75
0%
13.38%US$71.35US$50.01US$70.3411
Mar ’26n/a
US$62.28
0%
14.94%US$78.82US$50.10US$67.1111
Feb ’26US$50.00
US$60.51
+21.03%
16.07%US$76.33US$39.46n/a11
Jan ’26n/a
US$61.37
0%
16.91%US$72.22US$40.79US$54.2611
Dec ’25n/a
US$59.96
0%
16.91%US$70.56US$39.85US$58.4211
Nov ’25n/a
US$58.13
0%
19.02%US$71.08US$40.15n/a11
Oct ’25n/a
US$59.96
0%
16.00%US$70.96US$43.29US$57.3611
Sep ’25n/a
US$54.13
0%
17.92%US$67.04US$41.73n/a11
US$93.81
Fair Value
18.9% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/10 13:03
End of Day Share Price 2026/08/28 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Otsuka Holdings Co., Ltd. is covered by 19 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Miki SogiBernstein
Koichi MameganoBofA Global Research